first nab show efficaci monkey
number share mn
chg prev ep
estimate pot chg tp
dose escal phase studi follow pivot studi everyth
goe smooth might approv fall/wint
potenti usag patient high risk popul
given proven efficaci treatment infect monkey
protect reagent non-infect monkey could potenti
use patient high risk popul elderli peopl
hospit staff etc protect market attract
might even larger treatment market although multipl
vaccin develop still face big challeng
human efficaci larg scale product therefor
think nab like use short-term protect reagent
need popul ad protect market model
increas potenti sale without success rate
adjust bn exclud mileston incom
preclin data junshi nab show
good treatment protect efficaci
monkey think data packag appear thorough
convinc pave way smooth transit clinic phase
june view
first nab demonstr efficaci anim
model world among competitor show
posit cellular data therefor believ first
enter clinic phase month ahead competitor
everyth goe smoothli might approv fall/wint
could potenti use patient high-risk
popul elderli peopl hospit staff etc protect
market attract might even larger treatment
market increas sale bn
maintain outperform lift tp
increas revenu estim factor
potenti protect usag increas success rate
think stock upsid potenti driven continu
progress
treatment protect infect
capabl
preclin result junshi neutralis antibodi
nab publish natur one renown
scientif journal may think data posit
help smooth transit clinic stage expect june
inhibit infect disrupt interact
spike protein human angiotensin
domain rbd high affin nm vitro specif
crosstalk sars-cov mers-cov
importantli
monkey infect model studi show good treatment
exposur monkey reduc amount throat swab
monkey kept level baselin throughout studi
furthermor show could protect lung
caus damag post- pre-viru exposur monkey
thorough data packag demonstr efficaci differ
aspect view
first nab show efficaci anim model
first nab demonstr efficaci anim
model world global four major player develop
nab includ junshi/lilli regeneron
adapt junshi publish data show
posit cellular data two player yet reveal
result base believ would first enter
clinic phase month ahead competitor accord
manag junshi commun nmpa fda regard
clinic design file ind investig new drug
applic next week detail clinic plan expect
reveal upon ind file think clinic plan includ
pre-viru
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid report singl factor make invest
charl martineau univers toronto compani mention price
fei zheng jason liu certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part compens
directli indirectli relat specif recommend view express report
price rate histori inc amgn oq
signifi initi assumpt coverag
effect juli nc denot termin coverag
price rate histori inc regn oq
signifi initi assumpt coverag
charl martineau univers toronto price rate histori shanghai junshi bioscienc co ltd
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst
coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun octob
canadian well european exclud turkey rate base stock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres attract neutral less
attract underperform least attract invest opportun latin america turkey asia exclud japan australia
stock rate base stock total return rel averag total return relev countri region benchmark india
bse sensex index prior octob canadian rate base stock absolut total return potenti
current share price rel attract stock total return potenti within analyst coverag univers australian
new zealand stock expect total return calcul includ roll dividend yield outperform rate assign
greater equal under-perform less equal neutral may assign
overlap rate rang allow analyst assign rate put context associ risk
prior may rang outperform under-perform rate overlap neutral threshold
oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
circumst
rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate
invest view equiti secur compani relat product
volatil indic stock defin volatil stock price move month least
past month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector
credit suiss distribut stock rate bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform
